Please use this identifier to cite or link to this item:
|Title:||Interferon-alpha therapy within the first year after acute hepatitis C infection in hernodialysis patients: efficacy and tolerance|
|Authors:||Rocha, Cristina M. [UNIFESP]|
Perez, Renata M.
Narciso, Janaina L. [UNIFESP]
Ferreira, Adalgisa P. [UNIFESP]
Lemos, Lara B. [UNIFESP]
Medina-Pestana, Jose O. [UNIFESP]
Silva, Antonio Eduardo B. [UNIFESP]
Ferraz, Maria Lucia G. [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Universidade Federal do Rio de Janeiro (UFRJ)
|Keywords:||acute hepatitis C|
end-stage renal disease
|Publisher:||Lippincott Williams & Wilkins|
|Citation:||European Journal of Gastroenterology & Hepatology. Philadelphia: Lippincott Williams & Wilkins, v. 19, n. 2, p. 119-123, 2007.|
|Abstract:||Background Interferon monotherapy significantly reduces the chronicity rate of acute hepatitis C in nonuremic patients. in this clinical study, we evaluated the efficacy and tolerance of interferon-alpha( therapy for acute hepatitis C in hemodialysis patients.Methods Patients with acute hepatitis C, established on the basis of seroconversion to anti-hepatitis C virus and the presence of hepatitis C virus RNA, received a low dose of interferon-alpha (3 MU three times per week) for 12 months or a high dose (5 MU three times per week, preceded by a daily induction dose) for 6 months. Response to treatment was defined as undetectable hepatitis C virus RNA at the end of treatment and sustained virological response was defined as persistent negative hepatitis C virus RNA 6 months after the end of treatment.Results Twenty-three patients were treated, 16 with a low dose of interferon-alpha and seven with a high dose. At the end of treatment, hepatitis C virus RNA was undetectable in 16/ 23 patients (70%). of these, 6/23 patients (26%) relapsed and 10/23 (43%) maintained a sustained virological response (38% in lower doses vs. 57% in higher doses). Treatment was well tolerated and only three patients discontinued therapy (13%).Conclusion Interferon-a within the first year after acute hepatitis C in hemodialysis patients was found to be safe and effective, inducing a sustained virological response in 43% of cases. This study supports the routine indication of acute hepatitis C treatment with interferon-alpha for hemodialysis patients, and higher doses administered for a shorter period of time should be tried according to the tolerance of the patients.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.